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To the Editor:
The Psychiatric Genomics Consortium (PGC) (www.med.unc. 
edu/pgc) is delivering an increasing flow of discoveries about 
the fundamental basis of psychiatric disorders. Moving from 
the discovery of genome-wide association study (GWAS) loci 
toward delivering new therapeutic approaches is a challenge 
that requires a new wave of multidisciplinary work and close 
liaison between academia and industry. The PGC has recently 
initiated a new research program to deliver “actionable” find-
ings that 1) reveal the fundamental biology of psychiatric dis-
orders, 2) inform clinical practice, and 3) deliver new 
therapeutic targets. Working with industry will be essential, but 
there is a lack of a forum to exchange ideas with academia. 
With the aim of filling this gap, the first PGC Pathways to Drugs 
industry–academia workshop was held at the Institute of 
Psychiatry, Psychology and Neuroscience, King’s College 
London on March 2 and 3, 2017. We review the main advances 
in the field (1).
The PGC works on schizophrenia, bipolar disorder, 
major depressive disorder, autism spectrum disorder, eating 
disorders, posttraumatic stress disorder, attention-deficit/
hyperactivity disorder, Alzheimer’s disease, obsessive-
compulsive disorder, Tourette syndrome, and substance use 
disorders. The PGC has identified more than 300 genetic as-
sociations in seven disorders and the aim of the next 5 years is 
to increase sample sizes to more than 100,000 cases for each 
psychiatric disorder and find new treatments (1). There is 
considerable potential for the knowledge derived from GWASs 
to revitalize industry drug discovery efforts (2). In addition, the 
complex nature of psychiatric disorders means that the study 
of biological pathways is also of paramount importance (3).
Strong examples of translation are emerging, exemplified by 
the new anorexia GWAS results, which are inspiring a recon-
ceptualization of anorexia nervosa as both a metabolic and 
psychiatric disorder (4). Major contributions to the PGC from 
the Lundbeck Foundation Initiative for Integrative Psychiatric 
Research and others are advancing the genetics of attention-
deficit/hyperactivity disorder and autism spectrum disorder 
(1). Likewise, the UK Biobank (5) (www.ukbiobank.ac.uk) is an
extensive resource of approximately 500,000 genotyped in-
dividuals. UK Biobank mental health phenotyping on 157,000 
patients is available and will reach more than 300,000 in-
dividuals, meaning that the UK Biobank will become the largest 
cohort with mental health questionnaire data worldwide (1). 
Multiple psychiatric disorders are achieving successful 
GWASs, leading to the hope that new therapeutic leads can be 
identified. Finally, the PGC is developing a pipeline for the 
identification of drug candidates using GWAS results (6). 
However, these hypotheses are only a first step in the drug 
discovery process and need to be followed up by functionaland pharmacological studies, in collaboration with industry,
and validated by clinical trials.
Determining mechanistic hypotheses arising from a GWAS
association is a general problem across medicine. Some re-
gions occasionally implicate a single gene with clarity; e.g.,
genetic evidence for major depressive disorder has highlighted
LRFN5, TCF4, PTPN1, and NEGR1. Other loci are intergenic
and far from any known genes; still other loci can contain many
genes or lie within regulatory regions. Connecting GWAS
findings to salient genes and mapping regulatory regions is
crucial to identifying targets.
Discussions at the conference focused on the integration of
three sets of methods. First, statistical methods to evaluate
gene sets, which have been used to demonstrate the salience
of major depressive disorder and schizophrenia GWAS find-
ings to the targets of antidepressant and antipsychotic medi-
cations (6,7). Second, bioinformatics approaches to leverage
functional genomic data [gene expression (2), DNA–DNA
looping (8), and epigenomics (9)]. Data from the National
Institute of Mental Health PsychENCODE Consortium on brain
samples from people with severe psychiatric disorders will
further enable this intent (9). Finally, large-scale genetic editing
may be needed (10). Together, the above steps can be used to
generate hypotheses, narrow an interval to include regulatory
regions, or identify key elements.
After identifying potentially relevant genes, a key challenge
is to determine which of the corresponding proteins are
“druggable” to find drugs that could bind to these proteins,
regulate their production, prevent protein–protein interactions,
or in any way have an influence on their biological mecha-
nism(s). These steps are enabled by chemoinformatics and
bioinformatics approaches encompassing machine learning,
molecular modelling, and data mining. There is an increasing
quality of data available in databases collecting drug/target
affinities (3) (ChEMBL, PHAROS, Ki DB, etc.). Open Targets
(www.targetvalidation.org) is a relatively new free platform that
collects target/phenotype associations from various sources
(including UniProt, GWAS Catalog, European Variation
Archive, and Gene2Phenotype). These public databases, many
partly funded by industry, are complemented by new open-
source drug laboratory resources that can be used to allow
screening of the entire druggable G protein–coupled receptor
receptorome (1).
Polygenic risk scores (PRSs) summarize an individual’s
genetic loading for a disorder in a single measure. Their power
is increasing, and it is now possible to calculate PRSs for
common side effect profiles, such as hypertension and type 2
diabetes. In designing clinical trials, the use of PRSs could
allow the recruitment of individuals at high genetic risk, or for
stratifying response. Post hoc analysis of PRSs in completed
clinical trials may improve the understanding of drug response
profiles and encourage the pharmaceutical industry to move
genetics earlier within the trial pipeline, to ultimately develop
companion diagnostics with PRSs. Using the power of clinical
trial samples will require interaction between the research
community and industry to test the utility of PRSs for improved
prescribing and clinical trials.
In conclusion, our discussions pointed out the need to
integrate multiple data sources to discover new treatments for
psychiatric disorders: gene expression in different tissues,
drug/target affinities, GWAS results, bioinformatics, chemo-
informatics, and pharmacogenomics. New drug development
could be further aided by the adoption of precision medicine
for psychiatric clinical trials, as exemplified by PRSs and
“precision psychiatry.” Ultimately, however, new drug discov-
ery in psychiatry will be best enabled if academia and industry
join forces and if open data- and sample-sharing initiatives are
encouraged. Joint industry–academia conferences will be
essential to achieve these goals, identify main research ob-
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